Sartans: from treatment of hypertension to management of cardiovascular risk


DOI: https://dx.doi.org/10.18565/therapy.2019.7.112-119

Chulkov V.S., Lenetz E.A.

South Ural State Medical University of the Ministry of Healthcare of Russia, Chelyabinsk
Angiotensin-receptor blockers (ARB) are one of four drug classes recommended for the initial treatment of hypertension. These medications are commonly used not only for hypertension, but also for heart failure and chronic kidney disease. Fimasartan, the ninth and latest ARB, is a pyrimidin-4(3H)-one derivative of losartan, which has replaced the imidazole ring. Fimasartan is a selective angiotensin II type 1 receptor antagonist. It provides a noncompetitive, insurmountable binding with this receptor. Preclinical studies have shown some potential pleiotropic mechanisms, including anti-inflammatory and organ-protection effects. In phase II clinical studies, fimasartan showed an excellent safety profile and at a dosage range 60–120 mg once daily showed an antihypertensive effect over 24 h. In phase III confirmatory clinical studies conducted using other Angiotensin Receptor Blockers as comparators, fimasartan was non-inferior to losartan and candesartan in reducing blood pressure and proved an effective blood pressure lowering effect greater than that of valsartan.
Keywords: fimasartan, efficacy, management, safety, hypertension
Read entire article

Literature

  1. Dezsi C.A. The different therapeutic choices with ARBs. Which one to give? When? Why? Am J Cardiovasc Drugs. 2016; 16: 255–66. doi: 10.1007/s40256-016-0165-4

  2. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 2018; 39: 3021–104. doi: 10.1093/eurheartj/ehy339

  3. Whelton P.K., Carey R.M., Aronow W.S., Casey D.E. Jr, Collins K.J., Dennison Himmelfarb C., DePalma S.M., Gidding S., Jamerson K.A., Jones D.W., MacLaughlin E.J., Muntner P., Ovbiagele B., Smith S.C. Jr, Spencer C.C., Stafford R.S., Taler S.J., Thomas R.J., Williams K.A. Sr, Williamson J.D. Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018; 71(6): 1269–324. doi: 10.1161/HYP.0000000000000065.

  4. Messerli F.H., Bangalore S., Bavishi C., Rimoldi S.F. Angiotensin-Converting Enzyme inhibitors in hypertension. To use or not to use? J Am Coll Cardiol. 2018; 71: 1474–82.

  5. Musini V.M., Fortin P.M., Bassett K., Wright J.M. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev. 2008; 4: CD007066.

  6. Heran B.S., Wong M.M., Heran I.K., Wright J.M. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2008; 4: CD003823.

  7. Heran B.S., Wong M.M., Heran I.K., Wright J.M. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2008; 4: CD003822.

  8. Messerli F.H., Makani H., Benjo A., Romero J., Alviar C., Bangalore S. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol. 2011; 57: 590–600.

  9. Bonner G., Bakris G.L., Sica D., Weber M.A., White W.B., Perez A., Cao C., Handley A., Kupfer S. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens. 2013; 27: 479–86.

  10. Ruilope L.M. Fixed-combination olmesartan/amlodipine was superior to perindopril + amlodipine in reducing central systolic blood pressure in hypertensive patients with diabetes. J Clin Hypertens (Greenwich). 2016; 18: 528–35.

  11. Omboni S., Malacco E., Mallion J.M., Volpe M., Zanchetti A. Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies. J Hypertens. 2012; 30: 1468–77.

  12. Law M.R., Wald N.J., Morris J.K., Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003; 326: 1427.

  13. Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145–53.

  14. Bangalore S., Fakheri R., Toklu B., Ogedegbe G., Weintraub H., Messerli F.H. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254 301 patients from randomized trials. Mayo Clin Proc. 2016; 91: 51–60.

  15. Ricci F., Di Castelnuovo A., Savarese G., Perrone Filardi P., De Caterina R. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure: a network meta-analysis. Int J Cardiol. 2016; 217: 128–34.

  16. Messerli F.H., Bangalore S. Angiotensin receptor blockers reduce cardiovascular events, including the risk of myocardial infarction. Circulation. 2017; 135: 2085–87.

  17. Nissen S.E., Tuzcu E.M., Libby P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004; 292: 2217–25.

  18. Nissen S.E., Tuzcu E.M., Libby P., Thompson P.D., Ghali M., Garza D., Berman L., Shi H., Buebendorf E., Topol E.J. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004; 292: 2217–25.

  19. McMurray J.J., Ostergren J., Swedberg K., Granger C.B., Held P., Michelson E.L., Olofsson B., Yusuf S., Pfeffer M.A. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003; 362: 767–71.

  20. Granger C.B., McMurray J.J., Yusuf S., Held P., Michelson E.L., Olofsson B., Ostergren J., Pfeffer M.A., Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003; 362: 772–76.

  21. Burnett H., Earley A., Voors A.A., Senni M., McMurray J.J., Deschaseaux C., Cope S. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circ Heart Fail. 2017; 10: e003529.

  22. Packer M., McMurray J.J.V. Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. Lancet. 2017; 389: 1831–40.

  23. Mann J.F., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Pogue J., Wang X., Maggioni A., Budaj A., Chaithiraphan S., Dickstein K., Keltai M., Metsärinne K., Oto A., Parkhomenko A., Piegas L.S., Svendsen T.L., Teo K.K., Yusuf . Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008; 372: 547–53.

  24. Xie X., Liu Y., Perkovic V., Li X., Ninomiya T., Hou W., Zhao N., Liu L., Lv J., Zhang H., Wang H. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016; 67: 728–41.

  25. Potier L., Roussel R., Elbez Y., Marre M., Zeymer U., Reid C.M., Ohman M., Eagle K.A., Bhatt D.L., Steg P.G. Angiotensinconverting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart. 2017; 103: 1339–46.

  26. Lin C.C., Wu Y.T., Yang W.C., Tsai M.J., Liu JS, Yang C.Y., Li S.Y., Ou S.M., Tarng D.C., Hsu C.C. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: a nationwide study of therapy with renin-angiotensin system blockade. PLoS One. 2017; 12: e0189126.

  27. Barnett A.H., Bain S.C., Bouter P., Karlberg B., Madsbad S., Jervell J., Mustonen J. Angiotensin-receptor blockade versus convertingenzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004; 351: 1952–61.

  28. Catala-Lopez F., Macias Saint-Gerons D., Gonzalez-Bermejo D., Rosano G.M., Davis B.R., Ridao M., Zaragoza A., Montero-Corominas D., Tobías A., de la Fuente-Honrubia C., Tabares-Seisdedos R., Hutton B. Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses. PLoS Med. 2016; 13: e1001971.

  29. Jezko P., Zufkova V., Remko M. Modelling of absorption, distribution and physicochemical properties of AT1 receptor antagonists. Acta Fac. Pharm. Univ. Comen. LXII. 2015; 2: 20–31. doi: 10.1515/afpuc-2015-0028

  30. Woo K.T., Wook Y.B., Kwang L.J. et al. Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists. Bioorg Med Chem Lett. 2012; 22: 1649–54.

  31. Lee S.E., Kim Y.J., Lee H.Y., Kim J.H., Lee K.T., Chi Y.H., Lee J.Y. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase iii, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. Clin Ther. 2012; 34: 552–68.

  32. Je H.K., Joo H.L., Soo H.P., Ji H.K., Yong H.Ch. Fimasartan, a novel angiotensin ii receptor antagonist. Arch Pharm Res. 2012; 35: 1123–26.

  33. Wang J., Ho L., Chen L., Zhao Z., Zhao W., Qian X., Humala N., Seror I., Bartholomew S., Rosendorff C., Pasinetti G.M. Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest. 2007; 117: 3393–402.

  34. Hoieggen A., Alderman M.H., Kjeldsen S.E., Julius S., Devereux R.B., De Faire U., Fyhrquist F., Ibsen H., Kristianson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Wedel H., Chen C., Dahlof B. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004; 65: 1041–49.

  35. Sato Y., Fujii S., Imagawa S., Ohmura K., Ohmura Y., Andoh Y., Dong J., Ishimori N., Furumoto T., Tsutsui H. Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers. J Atheroscler Thromb. 2007; 14: 31–35.

  36. Benson S.C., Iguchi R., Ho C.I., Yamamoto K., Kurtz T.W. Inhibition of cardiovascular cell proliferation by angiotensin receptor antagonists: are all molecules the same? J Hypertens. 2008; 26: 973–80.

  37. Remkova A., Kratochvilova H., Durina J. Impact of the therapy by renin–angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension. J Hum Hypertens. 2008; 22: 338–45.

  38. Han J., Park S.J., Thu V.T., Lee S.R., Long le T., Kim H.K., Kim N., Park S.W., Jeon E.S., Kim E.J., Yoon C.H., Cho G.Y., Choi D.J. Effects of the novel angiotensin II receptor type I antagonist, fimasartan on myocardial ischemia/reperfusion injury. Int J Cardiol. 2013; 168: 2851–59.

  39. Lee J.Y., Lee C.W., Kim W.J., Ahn J.M., Park D.W., Kang S.J., Lee S.W., Kim Y.H., Son W.C., Jung S., Park S.W., Park S.J. Antiatherosclerotic effects of the novel angiotensin receptor antagonist Fimasartan on plaque progression and stability in a rabbit model: a double-blind placebo controlled trial. J Cardiovasc Pharmacol. 2013; 62: 229–36.

  40. Chang S.A., Lim B.K., Lee Y.J., Hong M.K., Choi J.O., Jeon E.S. A novel angiotensin type I receptor antagonist, fimasartan, prevents doxorubicin-induced cardiotoxicity in rats. J Korean Med Sci. 2015; 30: 559–68.

  41. Jang-Hee Cho, Soon-Youn Choi, Hye-Myung Ryu, Eun-Joo Oh, Ju-Min Yook, Ji-Sun Ahn, Hee-Yeon Jung, Ji-Young Choi, Sun-Hee Park, Chan-Duck Kim, Yong-Lim Kim. Fimasartan attenuates renal ischemia-reperfusion injury by modulating inflammation-related apoptosis. Korean J Physiol Pharmacol. 2018; 22(6): 661–670. doi:10.4196/kjpp.2018.22.6.661

  42. Fimasartan. Am J Cardiovasc Drugs. 2011; 11(4): 249–52. doi: 10.2165/11533640000000000-00000.

  43. Lee H.Y., Oh B.H. Fimasartan: a new angiotensin receptor blocker. Drugs. 2016; 76(10): 1015–22. doi: 10.1007/s40265-016-0592-1.

  44. Park J.B., Sung K.-C., Kang S.-M., Cho E.J. Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study). American Journal of Cardiovascular Drugs. 2013; 13: 47–56. doi: 10.1007/s40256-013-0004-9 PMID: 23344912.

  45. Kim C., Kim M.Y., Kang D.R., Kim J.Y., Park J.B. The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics. Pulse (Basel). 2014 May; 1(3–4): 177–85. doi: 10.1159/000360965.

  46. Lee H., Kim K.S., Chae S.C., Jeong M.H., Kim D.S., Oh B.H. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel group study in Korean patients with mild to moderate essential hypertension. Clin Ther. 2013 Sep; 35(9): 1337–49. doi: 10.1016/j.clinthera.2013.06.021.

  47. Lee H.Y., Kim C.H., Song J.K., Chae S.C., Jeong M.H., Kim D.S., Byung-Hee Oh B.H. 24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension. Korean J Intern Med. 2017 Oct 17. doi: 10.3904/kjim.2016.094.

  48. Bulitta J.B., Paik S.H., Chi Y.H., Kim T.H., Shin S., Landersdorfer C.B., Jiao Y., Yadav R., Shin B. Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling. Eur J Pharm Sci. 2017 Sep 30; 107: 32–44. doi: 10.1016/j.ejps.2017.06.008.

  49. Angeli F., Verdecchia P., Trapasso M., Pane M., Signorotti S., Reboldi G. PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives, Expert Opinion on Drug Metabolism &Toxicology. 2018; 14: 533–41. doi: 10.1080/17425255.2018.1468435.

  50. Lee S.E., Kim Y.J., Lee H.Y. et al. Yang H.M., Park C.G., Kim J.J., Kim S.K., Rhee MY, Oh B.H. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. Clin Ther. 2012 Mar; 34(3): 552–568, 568 e1-9. doi: 10.1016/j.clinthera.2012.01.024.

  51. Youn J.C., Ihm S.H., Bae J.H., Park S.M., Jeon D.W., Jung B.C., Park T.H., Lee N.H., Song J.M., Yoon Y.W., Shin E.S., Sung K.C., Jung I.H., Pyun W.B., Joo S.J., Park W.J., Shin J.H., Kang S.M. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study. Clin Ther. 2014 Oct 01; 36(10): 1412–21. doi: 10.1016/j.clinthera.2014.07.004.

  52. Lee J.H., Yang D.H., Hwang J.Y., , Hur S.H., Cha T.J., Kim K.S., Kim M.H., Chun K.J., Cha G.S., Hong G.R., Lee S.G., Kim D.S., Kim D.I., Chae S.C.A Randomized, double-blind, candesartan-controlled, parallel group comparison clinical trial to evaluate the antihypertensive efficacy and safety of fimasartan in patients with mild to moderate essential hypertension. Clin Ther. 2016 Jun; 38(6): 1485–97. doi: 10.1016/j.clinthera.2016.04.005.

  53. Kim J.W., Yi S., Kim T.E., Lim K.S., Yoon S.H., Cho J.Y. Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. J Clin Pharmacol. 2013 Jan; 53(1): 75–81. doi: 10.1177/0091270011433328.

  54. Кобалава Ж.Д., Котовская Ю.В., Толкачева В.В., Корнева Е.В., Хозяинова Н.Ю., Самсонов М.Ю., Колода Д.Е., Конради А.О. Фармакокинетика фимасартана – нового представителя класса блокаторов АТ1‑рецепторов к ангиотензину II в российской популяции. Артериальная гипертензия. 2016; 22(3): 309–315. doi: 10.18705/1607-419X-2016-22-3-309-315.

  55. Звартау Н.Э., Вербицкая Е.В., Галанкин Т.Л., Конради А.О., Хозяинова Н.Ю., Самсонов М.Ю. Особенности антигипертензивной эффективности нового представителя класса антагонистов рецепторов к ангиотензину II – фимасартана при артериальной гипертензии 1–2-й степени: дополнительный анализ результатов предрегистрационного исследования в России. Артериальная гипертензия. 2018; 24(1): 110–119. doi: 10.18705/1607-419Х-2018-24-1-101-107

  56. Byrd J.B., Chertow G.M. , Bhalla V. Citation: hypertension hot potato – anatomy of the angiotensin-receptor blocker recalls. N Engl J Med. 2019; 380:1589–91. doi: 10.1056/NEJMp1901657.


About the Autors

Vasilii S. Chulkov, MD, professor of the Department of faculty therapy of South Ural State medical University of the Ministry of Healthcare of Russia. Address: 454092, Chelyabinsk, 64 Vorovsky Str. E-mail: vschulkov@rambler.ru
Elizaveta A. Lenetz, laboratory assistant of the Department of faculty therapy of South Ural State medical University of the Ministry of Healthcare of Russia. Address: 454092, Chelyabinsk, 64 Vorovsky Str. E-mail: liza.lenetz@yandex.ru


Similar Articles

Back to Content

Бионика Медиа